|Bid||13.06 x 43500|
|Ask||13.07 x 36900|
|Day's range||13.03 - 13.27|
|52-week range||5.48 - 14.42|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||0.04 (0.30%)|
|Ex-dividend date||05 Mar 2021|
|1y target est||N/A|
Current Lighting Solutions, LLC ("Current") and GE (NYSE:GE) today announced they have signed a collaboration agreement on small-size Potassium Fluorosilicate (PFS/KSF) phosphor for MiniLED and MicroLED applications for improved display technologies.
GE Healthcare today announced the acquisition of Zionexa, a leading innovator of in-vivo oncology and neurology biomarkers that help enable more personalized healthcare. The company aims to develop and bring to market Zionexa’s pipeline biomarkers, as well as the recently FDA-approved PET imaging agent, Cerianna™ (fluoroestradiol F-18), which is used as an adjunct to biopsy for the detection of estrogen receptor (ER) positive lesions to help inform treatment selection for patients with recurrent or metastatic breast cancer.
GE Renewable Energy’s Grid Solutions business (NYSE: GE) and Hitachi ABB Power Grids Ltd. announced today a non-exclusive, cross-licensing agreement related to the use of an alternative gas to sulfur hexafluoride (SF6) used in high voltage equipment. This fluoronitrile-based gas mixture has a significantly reduced impact on the environment compared to SF6.